{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:08:12Z","timestamp":1769638092019,"version":"3.49.0"},"reference-count":29,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tomography"],"abstract":"<jats:p>Objective: In this study, we aimed to compare [68Ga]FAPI PET\/CT and [18F]FDG PET\/CT imaging to detect lesions in multiple myeloma. Methods: A total of 14 patients with multiple myeloma who underwent [68Ga]FAPI PET\/CT and [18F]FDG PET\/CT imaging were included in this retrospective study. SUVmax values of [68Ga]FAPI and [18F]FDG were compared according to lesion locations. Also, lesion localization ability of both imaging methods was compared on the patient basis. Results: In 4 of 14 patients, [68Ga]FAPI PET\/CT and [18F]FDG PET\/CT have not detected any bone lesions. In 8 of the remaining 10 patients [18F]FDG PET\/CT detected bone lesions but in this group, 6 patients showed more higher SUVmax values than [18F]FDG PET\/CT in [68Ga]FAPI PET\/CT.In contrast, 2 of 8 patients showed more higher SUVmax values than [68Ga]FAPI PET\/CT in [18F]FDG PET\/CT. Moreover, [68Ga]FAPI PET\/CT detected bone lesions in two patients, which werenot detected by [18F]FDG PET\/CT. Also, in five patients, [68Ga]FAPI PET\/CT showed more bone lesions in comparison with[18F]FDG PET\/CT. Only one patient, [18F]FDG PET\/CT showed more bone lesions. Three extramedullary involvements were observed in the following locations: lung, presacral lymph node, and soft tissue mass lateral to the right maxillary sinus. Among these involvements, higher SUVmax values were observed in the lung and presacral lymph node with [68Ga]FAPI compared to [18F]FDG. However, the soft tissue mass showed a higher SUVmax value in [18F]FDG than [68Ga]FAPI. Conclusions: No significant superiority was observed in [68Ga]FAPI PET\/CT over [18F]FDG PET\/CT in patients with MM. However, [68Ga]FAPI PET\/CT can be utilized as a complementary imaging method to [18F]FDG PET\/CT in some settings, especially in low-[18F]FDG affinity and inconclusive cases. Considering the favorable aspects of [68Ga]FAPI PET\/CT in MM, such as low background activity, absence of non-specific bone marrow, and physiological brain involvement, further studies with a larger sample size should be conducted.<\/jats:p>","DOI":"10.3390\/tomography8010024","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T22:16:18Z","timestamp":1643753778000},"page":"293-302","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Comparison of [68Ga]-FAPI PET\/CT and [18F]-FDG PET\/CT in Multiple Myeloma: Clinical Experience"],"prefix":"10.3390","volume":"8","author":[{"given":"Umut","family":"Elboga","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Gaziantep University, Gaziantep 27310, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ertan","family":"Sahin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Gaziantep University, Gaziantep 27310, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf Burak","family":"Cayirli","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Gaziantep University, Gaziantep 27310, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merve","family":"Okuyan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Gaziantep University, Gaziantep 27310, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gokmen","family":"Aktas","sequence":"additional","affiliation":[{"name":"Department of Oncology, Medical Park Private Hospital, Gaziantep 27090, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Handan","family":"Haydaroglu Sahin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gaziantep University, Gaziantep 27310, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7552-6478","authenticated-orcid":false,"given":"Ilkay","family":"Dogan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Gaziantep University, Gaziantep 27310, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tulay","family":"Kus","sequence":"additional","affiliation":[{"name":"Department of Oncology, Gaziantep University, Gaziantep 27310, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dervis Murat","family":"Akkurd","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gaziantep University, Gaziantep 27310, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ufuk","family":"Cimen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Gaziantep University, Gaziantep 27310, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vuslat","family":"Mumcu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Gaziantep University, Gaziantep 27310, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benan","family":"Kilbas","sequence":"additional","affiliation":[{"name":"Department of R&D, Moltek Health Services Production & Marketing Inc., Kocaeli 41400, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf Zeki","family":"Celen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Gaziantep University, Gaziantep 27310, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/annonc\/mdi235","article-title":"Myeloma bone disease: Pathophysiology and management","volume":"16","author":"Terpos","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood-2018-08-825356","article-title":"Imaging in multiple myeloma: How? When?","volume":"133","author":"Zamagni","year":"2019","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","article-title":"Pathogenesis of myeloma bone disease","volume":"23","author":"Roodman","year":"2009","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1148\/rg.301095066","article-title":"Current concepts in the evaluation of multiple myeloma with MR imaging and FDG PET\/CT 1","volume":"30","author":"Hanrahan","year":"2010","journal-title":"Radiographics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.rcl.2021.05.003","article-title":"PET Imaging for Hematologic Malignancies","volume":"59","author":"Hughes","year":"2021","journal-title":"Radiol. Clin. N. Am."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00259-001-0711-3","article-title":"Initial results in the assessment of multiple myeloma using F-18 FDG PET","volume":"29","author":"Schirrmeister","year":"2002","journal-title":"Eur. J. Nucl. Med. Mol.Imaging"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3324\/haematol.10554","article-title":"A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma","volume":"92","author":"Zamagni","year":"2007","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s00256-006-0127-z","article-title":"Comparison of imaging with FDG PET\/CT with other imaging modalities in myeloma","volume":"35","author":"Beyer","year":"2006","journal-title":"Skeletal Radiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00259-018-4114-0","article-title":"18F-FDG PET\/ CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the revised International Staging System","volume":"46","author":"Jung","year":"2019","journal-title":"Eur. J.Nucl. Med. Mol. Imaging"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/MNM.0000000000001242","article-title":"Fluorodeoxyglucose-avid focal lesions and extramedullary disease on 18F-FDG PET\/computed tomography predict the outcomes of newly diagnosed symptomatic multiple myeloma patients","volume":"41","author":"Zhong","year":"2020","journal-title":"Nucl. Med.Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1073\/pnas.91.12.5657","article-title":"Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers","volume":"91","author":"Scanlan","year":"1994","journal-title":"Proc. Natl. Acad. Sci.USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"140409","DOI":"10.1016\/j.bbapap.2020.140409","article-title":"Molecular recognition of fibroblast activation protein for diagnostic and therapeutic applications","volume":"1868","author":"Busek","year":"2020","journal-title":"Biochim. Biophys. Acta (BBA)-Proteins Proteom."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","article-title":"Turning foes to friends: Targeting cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","article-title":"Development of novel FAP-targeted radiotracers with improved tumor retention","volume":"60","author":"Loktev","year":"2019","journal-title":"J.Nucl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"68Ga-FAPI PET\/CT: Biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAPI targeting agents in patients with various cancers","volume":"60","author":"Giesel","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"8Ga-FAPI PET\/CT: Tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J.Nucl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1148\/radiol.2311020452","article-title":"Multiple myeloma: Clinical review and diagnostic imaging","volume":"231","author":"Angtuaco","year":"2004","journal-title":"Radiology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.hoc.2016.03.007","article-title":"Imaging of Multiple Myeloma","volume":"30","author":"Amos","year":"2016","journal-title":"Hematol. Clin. N. Am."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1200\/EDBK_159009","article-title":"Updated Diagnostic Criteria and Staging System for Multiple Myeloma","volume":"35","author":"Rajkumar","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: A consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","article-title":"Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer","volume":"47","author":"Chen","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00259-020-04940-6","article-title":"Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET\/CT in patients presenting with inconclusive [18F]FDG PET\/CT findings","volume":"48","author":"Chen","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00259-021-05522-w","article-title":"The potential utility of [68Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [18F]FDG","volume":"49","author":"Lan","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Tomography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2379-139X\/8\/1\/24\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:12:26Z","timestamp":1760134346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2379-139X\/8\/1\/24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["tomography8010024"],"URL":"https:\/\/doi.org\/10.3390\/tomography8010024","relation":{},"ISSN":["2379-139X"],"issn-type":[{"value":"2379-139X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,1]]}}}